1,2-Dimethylimidazole | CAS:1739-84-0

We serve 1,2-Dimethylimidazole CAS:1739-84-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1,2-Dimethylimidazole

Chemical Name:1,2-Dimethylimidazole
CAS.NO:1739-84-0
Synonyms:1,2-Dimethylimidazole
1,2-Dimethyl-1H-imidazole
 
Physical and Chemical Properties:
Density 1.0±0.1 g/cm3
Boiling Point 206.0±0.0 °C at 760 mmHg
Melting Point 37-39 °C(lit.)
Molecular Formula C5H8N2
Molecular Weight 96.130
Flash Point 73.0±18.7 °C
Exact Mass 96.068748
PSA 17.82000
LogP -0.13
Vapour Pressure 0.3±0.3 mmHg at 25°C
Index of Refraction 1.519
 
Description:
Appearance:White crystalline powder
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Use:Intermediate of Organic synthesis.



Contact us for information like 2-Phenylimidazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2-Dimethyl-1H-imidazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Phenylimidazole Use and application,2-Phenylimidazole technical grade,usp/ep/jp grade.


Related News: API and raw material are often confused due to the similar usage of the two terms.Isopropyl 2-(3-Nitrobenzylidene)acetoacetate manufacturer The drug, Imfinzi, when added to chemotherapy and the drugmaker’s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.Bis(triethoxysilylpropyl) disulfide supplier The drug, Imfinzi, when added to chemotherapy and the drugmaker’s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.6-bromo-1H-pyridin-2-one vendor In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.Judging from the geographical distribution of enterprises, the largest distribution of API companies is Jiangsu and Zhejiang, with more than 300 enterprises; followed by Shandong, Sichuan and Hubei.